ReviewTheScientificWorldJournal2013
Efficacy of memantine, donepezil, or their association in moderate-severe Alzheimer's disease: a review of clinical trials.
Review in TheScientificWorldJournal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Verum- versus Sham-Acupuncture on Alzheimer's Disease (AD) in Animal Models: A Preclinical Systematic Review and Meta-Analysis.BioMed research international · 2020Pooled it
- Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: A meta-analysis.PloS one · 2017Pooled it
- A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence.Drugs & aging · 2015Pooled it
- Morphological and Molecular Profiling of Amyloid-β Species in Alzheimer's Pathogenesis.Molecular neurobiology · 2025Review
- Combined use of Donepezil and Memantine increases the probability of five-year survival of Alzheimer's disease patients.Communications medicine · 2024Article
- Cellular Mechanisms of Cognitive Enhancement: TheASN neuro · 2024Article
- Article
- New strategies of neurodegenerative disease treatment with extracellular vesicles (EVs) derived from mesenchymal stem cells (MSCs).Theranostics · 2023Review
- Blood-brain barrier leakage in Alzheimer's disease: From discovery to clinical relevance.Pharmacology & therapeutics · 2022Review
- Association between long-term usage of acetylcholinesterase inhibitors and lung cancer in the elderly: a nationwide cohort study.Scientific reports · 2022Article
- Current and Near-Future Treatment of Alzheimer's Disease.Current neuropharmacology · 2022Article
- Potentiation of cognitive enhancer effects of Alzheimer's disease medication memantine by alpha7 nicotinic acetylcholine receptor agonist PHA-543613 in the Morris water maze task.Psychopharmacology · 2021Article
- Neuroprotective derivatives of tacrine that target NMDA receptor and acetyl cholinesterase - Design, synthesis and biological evaluation.Computational and structural biotechnology journal · 2021Article
- Functional MRI technologies in the study of medication treatment effect on Alzheimer's disease.Aging medicine (Milton (N.S.W)) · 2018Review
- Combined Donepezil and Ethanolic Extract of Propolis Improved Memory Better Than Donepezil and Propolis Monotherapy in Wild TypeEvidence-based complementary and alternative medicine : eCAM · 2018Article
- Therapeutics of Neurotransmitters in Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2017Review
- Use of anti-dementia drugs in home care and residential care and associations with neuropsychiatric symptoms: a cross-sectional study.BMC geriatrics · 2015Article
- Article
- Comprehensive descriptive analysis of large Alzheimer's disease patient cohorts.Journal of Alzheimer's disease reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcetylcholinesterase (AChE)/cholinesterase (ChE) inhibitors (Is) and memantine are licensed for symptomatic treatment of mild-moderate and moderate-severe forms of Alzheimer's disease (AD), respectively. High doses of the AChE-I donepezil were licensed in the USA for moderate-severe AD, and the association AChE/ChE-Is plus memantine was proposed for AD at this stage.
objectivesThis paper has reviewed evidence from clinical trials of the effectiveness of memantine, donepezil, or the two drugs in association in managing moderate-severe AD.
methodDouble-blind, placebo-controlled randomized trials (RCTs) using memantine or donepezil alone or in association versus placebo in moderate-severe AD were reviewed. Analysis done in January 2013 considered the years 2007-2012. RESULTS AND
conclusionOnly 83 of the 941 papers selected were considered relevant, and only 13 met the criterion of "adequacy and representativeness." Memantine and donepezil lead to improvements in moderate-to-severe AD and the choice between the compounds should be based on their contraindications more than on disease severity. No evidence was found of advantages of the association of memantine-donepezil. The heterogeneity of conditions explored by RCTs, the relatively short time of observation (24-52 weeks), and the different cognitive assessment tools used did not allow comparing properly different trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.